NR1H4 and sclerosing cholangitis: Some FXR agonist drugs have shown good efficacy in the treatment of pathological cholestatic diseases including primary cholestatic diseases, cholangitis, primary sclerosing cholangitis, and cholangiocarcinoma31,32.